Price$6.11+0.02 (+0.25%)
01:30 PM07:45 PM
News · 26 weeks34-83%
2026-04-192026-10-11
Mix1990d
- Insider7(37%)
- Other5(26%)
- SEC Filings4(21%)
- Analyst2(11%)
- Earnings1(5%)
Latest news
25 items- PRAlumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures– Results build on ONWARD3 highest complete skin clearance (54% PASI 100) at Week 48, reinforcing envudeucitinib’s potential to become a leading oral therapy for moderate-to-severe plaque psoriasis – Patients switching from placebo or apremilast achieved rapid responses, comparable to those on continuous treatment at Week 48 – On track to submit an NDA for envudeucitinib in moderate-to-severe plaque psoriasis in 4Q 2026 SOUTH SAN FRANCISCO, Calif., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced new envudeucitinib data from the O
- INSIDERDirector Akkaraju Srinivas bought $10,726,255 worth of shares (986,721 units at $10.87) and sold $1,014,028 worth of shares (96,131 units at $10.55) (SEC Form 4)4 - ALUMIS INC. (0001847367) (Issuer)
- PRAlumis to Participate in Upcoming September Investor ConferencesSOUTH SAN FRANCISCO, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will participate in the following investor conferences: Wells Fargo 21st Annual Healthcare ConferenceSeptember 8-10, 2026, Boston, MAFireside chat: Tuesday, September 8, 2026 at 11:00 am ET Cantor Global Healthcare Conference September 9-11, 2026, New York, NY Fireside chat: Wednesday, September 9, 2026 at 2:10 pm ET Morgan Stanley Global Healthcare ConferenceSeptember 14-16, 2026, New York, NYFireside chat: Monday, September 14, 2026 at
- ANALYSTAlumis downgraded by GuggenheimGuggenheim downgraded Alumis from Buy to Neutral
- ANALYSTAlumis upgraded by H.C. Wainwright with a new price targetH.C. Wainwright upgraded Alumis from Neutral to Buy and set a new price target of $15.00
- SECAlumis Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - ALUMIS INC. (0001847367) (Filer)
- PRAlumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)– LUMUS trial did not meet its primary and secondary endpoints in the overall trial population – – Robust responses in the prespecified subgroup of patients with high interferon gene signature (IFNGS-high) support moving forward with Phase 3 development in SLE – – Pharmacodynamic data substantiate envudeucitinib’s potential in interferon-driven immune-mediated diseases – – Envudeucitinib was generally well tolerated with no new safety signals observed – – Alumis remains on track to submit an NDA for envudeucitinib in moderate-to-severe plaque psoriasis in 4Q 2026 – – Conference call and webcast scheduled for September 1 at 8:30 am EDT – SAN FRANCISCO, Sept. 01, 2026 (GLOBE NEWSWIRE)
- SECSEC Form 10-Q filed by Alumis Inc.10-Q - ALUMIS INC. (0001847367) (Filer)
- SECAlumis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ALUMIS INC. (0001847367) (Filer)
- PRAlumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements– ONWARD3: 54% of patients reached complete skin clearance (PASI 100) at 48 weeks, positioning envudeucitinib to set a new standard in PsO – – Alumis remains on track to submit its New Drug Application to FDA for envudeucitinib in moderate-to-severe plaque psoriasis (PsO) in Q4 2026 – – Potentially pivotal Phase 2b LUMUS topline data for envudeucitinib in SLE anticipated in Q3 2026 – SOUTH SAN FRANCISCO, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today reported financial results for the quarter ended June 30, 2026, and highlighted re
- SECAlumis Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - ALUMIS INC. (0001847367) (Filer)
- PREnvudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies– ONWARD3 data show 54% of patients reached complete skin clearance (PASI 100) after 48 weeks of continuous envudeucitinib treatment – – Favorable long-term safety and tolerability profile remained consistent with previously reported data – – On track to submit a New Drug Application to FDA in 4Q 2026 – SOUTH SAN FRANCISCO, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced topline results from the ongoing ONWARD3 long-term extension (LTE) study. Data confirm envudeucitinib delivered leading skin clearance and the highest rep
- SECSEC Form SCHEDULE 13G filed by Alumis Inc.SCHEDULE 13G - ALUMIS INC. (0001847367) (Subject)
- INSIDERChief Financial Officer Schroer John R. sold $86,546 worth of shares (3,282 units at $26.37), decreasing direct ownership by 12% to 24,718 units (SEC Form 4) (withholding obligation)4 - ALUMIS INC. (0001847367) (Issuer)
- INSIDERChief Legal Officer Pangali Sanam sold $35,969 worth of shares (1,364 units at $26.37), decreasing direct ownership by 12% to 9,747 units (SEC Form 4) (withholding obligation)4 - ALUMIS INC. (0001847367) (Issuer)
- INSIDERChief Business & Strategy Ofcr Hardiman Roy C. sold $70,988 worth of shares (2,692 units at $26.37), decreasing direct ownership by 1% to 207,746 units (SEC Form 4) (for tax liability)4 - ALUMIS INC. (0001847367) (Issuer)
- INSIDERChief Scientific Officer Goldstein David M sold $68,457 worth of shares (2,596 units at $26.37), decreasing direct ownership by 8% to 30,970 units (SEC Form 4) (for withholding tax)4 - ALUMIS INC. (0001847367) (Issuer)
- INSIDERChief Medical Officer Drappa Jorn sold $64,527 worth of shares (2,447 units at $26.37), decreasing direct ownership by 4% to 56,892 units (SEC Form 4) to cover withholding tax4 - ALUMIS INC. (0001847367) (Issuer)
- INSIDERChief Development Officer Bradley Mark Christopher sold $67,824 worth of shares (2,572 units at $26.37), decreasing direct ownership by 5% to 48,533 units (SEC Form 4) (tax withholding)4 - ALUMIS INC. (0001847367) (Issuer)
- INSIDERChief Legal Officer Pangali Sanam sold $140,000 worth of shares (5,000 units at $28.00) and exercised 5,000 shares at a strike of $5.06 (SEC Form 4)4 - ALUMIS INC. (0001847367) (Issuer)
- INSIDERDirector Tetrault Lynn A. was granted 3,553 shares (SEC Form 4)4 - ALUMIS INC. (0001847367) (Issuer)
- INSIDERDirector Yao Zhengbin was granted 3,553 shares, increasing direct ownership by 15% to 27,082 units (SEC Form 4)4 - ALUMIS INC. (0001847367) (Issuer)
- INSIDERDirector Srivastava Sapna was granted 3,553 shares (SEC Form 4)4 - ALUMIS INC. (0001847367) (Issuer)
- INSIDERDirector Machado Patrick was granted 3,553 shares (SEC Form 4)4 - ALUMIS INC. (0001847367) (Issuer)
- INSIDERDirector Akkaraju Srinivas was granted 3,553 shares (SEC Form 4)4 - ALUMIS INC. (0001847367) (Issuer)
ALMS FAQ
6 questionsWhere does ALMS stock trade?
Alumis Inc. (ALMS) is listed on NASDAQ.What sector and industry is ALMS in?
Alumis Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Alumis Inc. go public?
Alumis Inc. (ALMS) completed its IPO in 2024.What are analysts saying about ALMS?
Alumis Inc. has had 8 recent analyst actions on file. The most recent action was from Guggenheim: Neutral on 2026-09-03. Recent price targets range from $1500.00 to $4600.00.What companies are similar to ALMS?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ALMS side-by-side with any of them on Quantisnow.How can I track ALMS on Quantisnow?
Quantisnow aggregates Alumis Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ALMS to receive live email and push alerts on every new disclosure.